The global cancer biomarkers market was valued at US$ 13.2 Bn in the year 2018 and is expected to reach US$ 35.3 Bn by the year 2026, growing at a CAGR of 13.1%.
A biomarker is any naturally-occurring gene or molecule which is a measurable indicator of the presence or severity of a disease. Cancer biomarkers are processes or substances indicative of the presence of cancer in the body. Biomarkers may be secreted by cancer cells or by other cells in response to the presence of cancer.
Cancer biomarkers are present in blood, urine, stool, and other body fluids, and therefore, most of them can be non-invasively assayed. Cancer biomarkers are one of the best tools for early diagnosis, and it helps in prognosis and in predicting therapeutic responses as well.
The major factors that are driving the growth of the cancer biomarkers market are technological advancements in companion diagnostics and the development of new cancer biomarkers. Cancer biomarkers can be used for monitoring the response to treatment, and also for optimizing treatment and thereby help improve patient outcomes. Apart from these, the rising incidence of cancer and increasing government support will help drive the growth of the market.
The cancer biomarkers market report covers an in-depth analysis of the market including statistical and subjective data points, along with the key market drivers and opportunities & restraints that have positive or negative effects on the overall global market. An in-depth analysis of the regional and country level market at the various segment and sub-segment levels has been provided. The report comprises a competitive analysis of the key players functioning in the market and covers in-depth data related to the competitive landscape of the market and the recent strategies & product launches that will assist or affect the market in the near future.
Protein biomarkers to account for a major share in the market
Protein biomarkers testing is effective in cancer diagnosis, prognosis, and other therapeutic and clinical applications. Protein biomarker testing is relatively cheap, as compared to genetic biomarkers testing. Genetic biomarker testing is, however, more efficient and therefore, more reliable for cancer diagnosis and prognosis. Therefore, genetic biomarker testing is expected to grow at a significant rate during the forecast period. Apart from this, technological developments and rising adoption of genomic technologies such as Next generation sequencing (NGS) and Polymerase Chain Reaction (PCR) will also drive the market for genetic biomarkers segment.
Breast, Prostate, and lung cancer together account for a major share of the cancer biomarkers market
Based on cancer type, the market is segmented into lung cancer, prostate cancer, breast cancer, colorectal cancer, leukemia, and other cancers. Breast, prostate, and lung cancer account for a majority share in the market; the major factor being the high incidence of these cancers. Apart from this, a high level of awareness about the importance of early diagnosis of breast cancer is another reason due to which the cancer biomarker market for breast cancer is growing. HER2 gene and its proteins have been used as a biomarker for the early detection and diagnosis of breast cancer.
Lung cancer is expected to exhibit significant growth during the forecast period. The identification of new biomarkers and the development of increasing number of diagnostic tests that target the BRAF
essential for the diagnosis of non-small cell lung cancer.
North America to dominate the global cancer biomarkers market
North America is expected to hold a major share in the cancer biomarkers market and is expected to retain this share throughout the forecast period. The high prevalence of cancer, coupled with the adoption of new technologies such as OMICS technologies, is expected to drive the growth of the market. The increasing support given to research and development by government and private institutes is further driving the cancer biomarkers market in this region. Apart from this, the presence of major market players in this region is also one of the important factors to drive this market.
The Asia-Pacific region is expected to show significant growth during the forecast period, mainly driven by the economic growth in China, India, and Japan. The high prevalence of cancer in this region, coupled with the increasing demand for better diagnostics and treatment solutions, is expected to propel the market during the forecast period. Additionally, government and research institutes in this region are increasingly spending on R&D, which is further driving the market.
Company Profiles and Competitive Intelligence:
The notable players operating in the cancer biomarkers market are Abbott Laboratories (US), Affymetrix Inc. (US), Agilent Technologies (US), Becton, Dickinson and Company (US), bioMérieux SA (France), F. Hoffman La Roche (Switzerland), Hologic, Inc. (US), Merck & Co. (US), and Qiagen (Germany), amongst others.
Companies are investing in research and development of new cancer biomarkers and are also adopting inorganic strategies of growth such as mergers and acquisitions. For instance, in May 2016, Roche received the FDA approval for its VENTANA PD-L1 (SP142) Assay as a complementary
diagnostic that give the PD-L1 status of metastatic urothelial cancer patients considering treatment with TECENTRIQ™ (atezolizumab), which is an FDA approved immunotherapy.
Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Approach Adopted
1.3.4.1 Top-Down Approach
1.3.4.2 Bottom-Up Approach
1.3.5 Assumptions
1.4 Market Segmentation Scope
Chapter 2 Executive Summary
2.1 Market Summary
2.1.1 Global Cancer Biomarkers Market, 2016-2026, (US$ Mn)
2.1 Market Snapshot: Global Cancer Biomarkers Market
2.2 Market Dynamics
2.3 Global Cancer Biomarkers Market, by Segment, 2018
2.3.1 Global Cancer Biomarkers Market, by Biomarker Type, 2018 (US$ Mn)
2.3.2 Global Cancer Biomarkers Market, by Profiling Technology, 2018 (US$ Mn)
2.3.3 Global Cancer Biomarkers Market, by Cancer Type, 2018 (US$ Mn)
2.3.4 Global Cancer Biomarkers Market, by Application, 2018 (US$ Mn)
2.3.5 Global Cancer Biomarkers Market, by Region, 2018 (US$ Mn)
2.4 Premium Insights
2.4.1 Cancer Biomarkers Market In developed vs. developing Economies, 2018 vs 2026
2.4.2 Global Cancer Biomarkers Market: Regional Life Cycle Analysis
Chapter 3 Market Dynamics
3.1 Market Overview
3.2 Market Drivers
3.2.1 Increasing incidence of Cancer
3.2.2 Increasing use of cancer biomarkers in drug discovery and development
3.2.3 Technological Advancements
3.3 Market Restraints
3.3.1 High Cost
3.3.2 Unfavourable reimbursement scenario
3.4 Market Opportunities
3.4.1 Increasing demand from emerging countries
3.4.2 Personalized Medicine
3.4.3 Companion Diagnostics
Chapter 4 Global Cancer Biomarkers Market, by Biomarker Type
4.1 Market Overview, by Biomarker Type
4.1.1 Global Cancer Biomarkers Market, by Biomarker Type, 2016-2026 (US$ Mn)
4.1.2 Incremental Opportunity, by Biomarker Type, From 2018-2026
4.2 Genetic Biomarkers
4.2.1 Global Cancer Biomarkers Market, by Genetic Biomarkers, 2016-2026, (US$ Mn)
4.3 Protein Biomarkers
4.3.1 Global Cancer Biomarkers Market, by Protein Biomarkers, 2016-2026, (US$ Mn)
4.4 Other Biomarkers
4.4.1 Global Cancer Biomarkers Market, by Other Biomarkers, 2016-2026, (US$ Mn)
Chapter 5 Global Cancer Biomarkers Market, by Profiling Technology
5.1 Market Overview, by Profiling Technology
5.1.1 Global Cancer Biomarkers Market, by Profiling Technology, 2016-2026 (US$ Mn)
5.1.2 Incremental Opportunity, by Profiling Technology, From 2018-2026
5.2 Imaging Technology
5.2.1 Global Cancer Biomarkers Market, by Imaging Technology, 2016-2026, (US$ Mn)
5.3 OMICS Technology
5.3.1 Global Cancer Biomarkers Market, by OMICS Technology, 2016-2026, (US$ Mn)
5.4 Bioinformatics
5.4.1 Global Cancer Biomarkers Market, by Bioinformatics, 2016-2026, (US$ Mn)
5.5 Immunoassays
5.5.1 Global Cancer Biomarkers Market, by Immunoassays, 2016-2026, (US$ Mn)
5.6 Cytogenetics
5.6.1 Global Cancer Biomarkers Market, by Cytogenetics, 2016-2026, (US$ Mn)
Chapter 6 Global Cancer Biomarkers Market, by Cancer Type
6.1 Market Overview, by Cancer Type
6.1.1 Global Cancer Biomarkers Market, by Cancer Type, 2016-2026 (US$ Mn)
6.1.2 Incremental Opportunity, by Cancer Type, From 2018-2026
6.2 Lung Cancer
6.2.1 Global Cancer Biomarkers Market, by Lung Cancer, 2016-2026, (US$ Mn)
6.3 Prostate Cancer
6.3.1 Global Cancer Biomarkers Market, by Prostate Cancer, 2016-2026, (US$ Mn)
6.4 Colorectal Cancer
6.4.1 Global Cancer Biomarkers Market, by Colorectal Cancer, 2016-2026, (US$ Mn)
6.5 Breast Cancer
6.5.1 Global Cancer Biomarkers Market, by Breast Cancer, 2016-2026, (US$ Mn)
6.6 Leukemia
6.6.1 Global Cancer Biomarkers Market, by Leukemia, 2016-2026, (US$ Mn)
6.7 Others Cancers
6.7.1 Global Cancer Biomarkers Market, by Others Cancers, 2016-2026, (US$ Mn)
Chapter 7 Global Cancer Biomarkers Market, by Application
7.1 Market Overview, by Application
7.1.1 Global Cancer Biomarkers Market, by Application, 2016-2026 (US$ Mn)
7.1.2 Incremental Opportunity, by Application, From 2018-2026
7.2 Diagnostic
7.2.1 Global Cancer Biomarkers Market, by Diagnostic, 2016-2026, (US$ Mn)
7.3 Prognostic
7.3.1 Global Cancer Biomarkers Market, by Prognostic, 2016-2026, (US$ Mn)
7.4 Drug Discovery and Development
7.4.1 Global Cancer Biomarkers Market, by Drug Discovery and Development, 2016-2026, (US$ Mn)
7.5 Other Applications
7.5.1 Global Cancer Biomarkers Market, by Other Applications, 2016-2026, (US$ Mn)
Chapter 8 Global Cancer Biomarkers Market, by Region
8.1 Market Overview, by Region
8.1.1 Global Cancer Biomarkers Market, by Region, 2016-2026, (US$ Mn)
8.2 Attractive Investment Opportunity, by Region, 2018
8.3 North America Cancer Biomarkers Market
8.3.1 North America Cancer Biomarkers Market, by Biomarker Type, 2016-2026 (US$ Mn)
8.3.2 North America Cancer Biomarkers Market, by Profiling Technology, 2016-2026 (US$ Mn)
8.3.3 North America Cancer Biomarkers Market, by Cancer Type, 2016-2026 (US$ Mn)
8.3.4 North America Cancer Biomarkers Market, by Application, 2016-2026 (US$ Mn)
8.3.5 United States Country Profile
8.3.5.1 United States Cancer Biomarkers Market, 2016-2026 (US$ Mn)
8.3.6 Canada Country Profile
8.3.6.1 Canada Cancer Biomarkers Market, 2016-2026 (US$ Mn)
8.4 Europe Cancer Biomarkers Market
8.4.1 Europe Cancer Biomarkers Market, by Biomarker Type, 2016-2026 (US$ Mn)
8.4.2 Europe Cancer Biomarkers Market, by Profiling Technology, 2016-2026 (US$ Mn)
8.4.3 Europe Cancer Biomarkers Market, by Cancer Type, 2016-2026 (US$ Mn)
8.4.4 Europe Cancer Biomarkers Market, by Application, 2016-2026 (US$ Mn)
8.4.5 United Kingdom Country Profile
8.4.5.1 United Kingdom Cancer Biomarkers Market, 2016-2026 (US$ Mn)
8.4.6 Germany Country Profile
8.4.6.1 Germany Cancer Biomarkers Market, 2016-2026 (US$ Mn)
8.4.7 France Country Profile
8.4.7.1 France Cancer Biomarkers Market, 2016-2026 (US$ Mn)
8.4.8 Italy Country Profile
8.4.8.1 Italy Cancer Biomarkers Market, 2016-2026 (US$ Mn)
8.4.9 Spain Country Profile
8.4.9.1 Spain Cancer Biomarkers Market, 2016-2026 (US$ Mn)
8.4.10 Rest of Europe
8.4.10.1 Rest of Europe Cancer Biomarkers Market, 2016-2026 (US$ Mn)
8.5 Asia Pacific Cancer Biomarkers Market
8.5.1 Asia-Pacific Cancer Biomarkers Market, by Biomarker Type, 2016-2026 (US$ Mn)
8.5.2 Asia-Pacific Cancer Biomarkers Market, by Profiling Technology, 2016-2026 (US$ Mn)
8.5.3 Asia-Pacific Cancer Biomarkers Market, by Cancer Type, 2016-2026 (US$ Mn)
8.5.4 Asia-Pacific Cancer Biomarkers Market, by Application, 2016-2026 (US$ Mn)
8.5.5 China Country Profile
8.5.5.1 China Cancer Biomarkers Market, 2016-2026 (US$ Mn)
8.5.6 Japan Country Profile
8.5.6.1 Japan Cancer Biomarkers Market, 2016-2026 (US$ Mn)
8.5.7 India Country Profile
8.5.7.1 India Cancer Biomarkers Market, 2016-2026 (US$ Mn)
8.5.8 South Korea Country Profile
8.5.8.1 South Korea Cancer Biomarkers Market, 2016-2026 (US$ Mn)
8.5.9 Rest of Asia Pacific
8.5.9.1 Rest of Asia Pacific Cancer Biomarkers Market, 2016-2026 (US$ Mn)
8.6 Rest of the World Cancer Biomarkers Market
8.6.1 Rest of the World Cancer Biomarkers Market, by Biomarker Type, 2016-2026 (US$ Mn)
8.6.2 Rest of the World Cancer Biomarkers Market, by Profiling Technology, 2016-2026 (US$ Mn)
8.6.3 Rest of the World Cancer Biomarkers Market, by Cancer Type, 2016-2026 (US$ Mn)
8.6.4 Rest of the World Cancer Biomarkers Market, by Application, 2016-2026 (US$ Mn)
8.6.5 Latin America
8.6.5.1 Latin America Cancer Biomarkers Market, 2016-2026 (US$ Mn)
8.6.6 Middle East & Africa
8.6.6.1 Middle East & Africa Cancer Biomarkers Market, 2016-2026 (US$ Mn)
Chapter 9 Competitive Intelligence
9.1 Market Players Present in Market Life Cycle
9.2 Top 5 Players Comparison
9.3 Market Positioning of Key Players, 2018
9.4 Market Players Mapping
9.4.1 By Biomarker Type
9.4.2 By Application
9.4.3 By Region
9.5 Strategies Adopted by Key Market Players
9.6 Recent Developments in the Market
9.6.1 Mergers & Acquisitions, Partnership, New Product Developments
9.7 Operational Efficiency Comparison by Key Players
Chapter 10 Company Profiles
10.1 Abbott Laboratories
10.1.1 Abbott Laboratories Overview
10.1.2 Key Stakeholders/Person in Abbott Laboratories
10.1.3 Abbott Laboratories Products Portfolio
10.1.4 Abbott Laboratories Financial Overview
10.1.5 Abbott Laboratories News/Recent Developments
10.2 Affymetrix Inc.
10.2.1 Affymetrix Inc. Overview
10.2.2 Key Stakeholders/Person in Affymetrix Inc.
10.2.3 Affymetrix Inc. Products Portfolio
10.2.4 Affymetrix Inc. Financial Overview
10.2.5 Affymetrix Inc. News/Recent Developments
10.3 Agilent Technologies
10.3.1 Agilent Technologies Overview
10.3.2 Key Stakeholders/Person in Agilent Technologies
10.3.3 Agilent Technologies Products Portfolio
10.3.4 Agilent Technologies Financial Overview
10.3.5 Agilent Technologies News/Recent Developments
10.4 Becton, Dickinson and Company
10.4.1 Becton, Dickinson and Company Overview
10.4.2 Key Stakeholders/Person in Becton, Dickinson and Company
10.4.3 Becton, Dickinson and Company Products Portfolio
10.4.4 Becton, Dickinson and Company Financial Overview
10.4.5 Becton, Dickinson and Company News/Recent Developments
10.5 BioMérieux SA
10.5.1 BioMérieux SA Overview
10.5.2 Key Stakeholders/Person in BioMérieux SA
10.5.3 BioMérieux SA Products Portfolio
10.5.4 BioMérieux SA Financial Overview
10.5.5 BioMérieux SA News/Recent Developments
10.6 F. Hoffman La Roche
10.6.1 F. Hoffman La Roche Overview
10.6.2 Key Stakeholders/Person in F. Hoffman La Roche
10.6.3 F. Hoffman La Roche Products Portfolio
10.6.4 F. Hoffman La Roche Financial Overview
10.6.5 F. Hoffman La Roche News/Recent Developments
10.7 Hologic, Inc
10.7.1 Hologic, Inc Overview
10.7.2 Key Stakeholders/Person in Hologic, Inc
10.7.3 Hologic, Inc Products Portfolio
10.7.4 Hologic, Inc Financial Overview
10.7.5 Hologic, Inc News/Recent Developments
10.8 Merck & Co.
10.8.1 Merck & Co. Overview
10.8.2 Key Stakeholders/Person in Merck & Co.
10.8.3 Merck & Co. Products Portfolio
10.8.4 Merck & Co. Financial Overview
10.8.5 Merck & Co. News/Recent Developments
10.9 Qiagen
10.9.1 Qiagen Overview
10.9.2 Key Stakeholders/Person in Qiagen
10.9.3 Qiagen Products Portfolio
10.9.4 Qiagen Financial Overview
10.9.5 Qiagen News/Recent Developments
TABLE 1 Market Snapshot: Global Cancer Biomarkers Market Value
TABLE 2 Global Cancer Biomarkers Market, by Biomarker Type, 2016-2026 (US$ Mn)
TABLE 3 Global Cancer Biomarkers Market, by Profiling Technology, 2016-2026 (US$ Mn)
TABLE 4 Global Cancer Biomarkers Market, by Cancer Type, 2016-2026 (US$ Mn)
TABLE 5 Global Cancer Biomarkers Market, by Application, 2016-2026 (US$ Mn)
TABLE 6 Global Cancer Biomarkers Market, by Region, 2016-2026 (US$ Mn)
TABLE 7 North America Cancer Biomarkers Market, by Biomarker Type, 2016-2026 (US$ Mn)
TABLE 8 North America Cancer Biomarkers Market, by Profiling Technology, 2016-2026 (US$ Mn)
TABLE 9 North America Cancer Biomarkers Market, by Cancer Type, 2016-2026 (US$ Mn)
TABLE 10 North America Cancer Biomarkers Market, by Application, 2016-2026 (US$ Mn)
TABLE 11 Europe Cancer Biomarkers Market, by Biomarker Type, 2016-2026 (US$ Mn)
TABLE 12 Europe Cancer Biomarkers Market, by Profiling Technology, 2016-2026 (US$ Mn)
TABLE 13 Europe Cancer Biomarkers Market, by Cancer Type, 2016-2026 (US$ Mn)
TABLE 14 Europe Cancer Biomarkers Market, by Application, 2016-2026 (US$ Mn)
TABLE 15 Asia-Pacific Cancer Biomarkers Market, by Biomarker Type, 2016-2026 (US$ Mn)
TABLE 16 Asia-Pacific Cancer Biomarkers Market, by Profiling Technology, 2016-2026 (US$ Mn)
TABLE 17 Asia-Pacific Cancer Biomarkers Market, by Cancer Type, 2016-2026 (US$ Mn)
TABLE 18 Asia-Pacific Cancer Biomarkers Market, by Application, 2016-2026 (US$ Mn)
TABLE 19 Rest of the World Cancer Biomarkers Market, by Biomarker Type, 2016-2026 (US$ Mn)
TABLE 20 Rest of the World Cancer Biomarkers Market, by Profiling Technology, 2016-2026 (US$ Mn)
TABLE 21 Rest of the World Cancer Biomarkers Market, by Cancer Type, 2016-2026 (US$ Mn)
TABLE 22 Rest of the World Cancer Biomarkers Market, by Application, 2016-2026 (US$ Mn)
TABLE 23 Top 5 Players Comparison
TABLE 24 Market Players Mapping – By Biomarker Type
TABLE 25 Top Players Market Mapping – By Application
TABLE 26 Top Players Market Mapping – By Region
TABLE 27 Strategies Adopted by Key Market Players
TABLE 28 Mergers & Acquisitions, Partnership, New Product Developments
TABLE 29 Abbott Laboratories Overview
TABLE 30 Key Stakeholders/Person in Abbott Laboratories
TABLE 31 Abbott Laboratories Product Portfolio
TABLE 32 Abbott Laboratories News/Recent Developments
TABLE 33 Affymetrix Inc. Overview
TABLE 34 Key Stakeholders/Person in Affymetrix Inc.
TABLE 35 Affymetrix Inc. Product Portfolio
TABLE 36 Affymetrix Inc. News/Recent Developments
TABLE 37 Agilent Technologies Overview
TABLE 38 Key Stakeholders/Person in Agilent Technologies
TABLE 39 Agilent Technologies Product Portfolio
TABLE 40 Agilent Technologies News/Recent Developments
TABLE 41 Becton, Dickinson and Company Overview
TABLE 42 Key Stakeholders/Person in Becton, Dickinson and Company
TABLE 43 Becton, Dickinson and Company Product Portfolio
TABLE 44 Becton, Dickinson and Company News/Recent Developments
TABLE 45 BioMérieux SA Overview
TABLE 46 Key Stakeholders/Person in BioMérieux SA
TABLE 47 BioMérieux SA Product Portfolio
TABLE 48 BioMérieux SA News/Recent Developments
TABLE 49 F. Hoffman La Roche Overview
TABLE 50 Key Stakeholders/Person in F. Hoffman La Roche
TABLE 51 F. Hoffman La Roche Product Portfolio
TABLE 52 F. Hoffman La Roche News/Recent Developments
TABLE 53 Hologic, Inc Overview
TABLE 54 Key Stakeholders/Person in Hologic, Inc
TABLE 55 Hologic, Inc Product Portfolio
TABLE 56 Hologic, Inc News/Recent Developments
TABLE 57 Merck & Co. Overview
TABLE 58 Key Stakeholders/Person in Merck & Co.
TABLE 59 Merck & Co. Product Portfolio
TABLE 60 Merck & Co. News/Recent Developments
TABLE 61 Qiagen Overview
TABLE 62 Key Stakeholders/Person in Qiagen
TABLE 63 Qiagen Product Portfolio
TABLE 64 Qiagen News/Recent Developments
